NXTC Reports 55% ORR for SIM0505 in Gynecologic Cancers, 52.9% in Ovarian Cancer, Favorable Safety Profile in Phase 1 Trial
NextCure, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $6.20
+11% in 1h after detection
Post-detection moves
1h
+11%
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS